Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 17 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/5/2007 First Published: 5/1/1999


1.		Phase III Randomized Study of Ciprofloxacin vs Cephalexin in Patients with Stage Ta Transitional Cell Carcinoma of the Bladder Treated with Transurethral Tumor Resection

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				SWOG-S9809 CLB-S9809, NCT00003824, S9809


2.		Phase III Empirical Antimicrobial Therapy vs Early Open Lung Biopsy/Specific Therapy for Diffuse Interstitial Pneumonitis in Immunocompromised Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Completed				no age specified								NCI-82-C-111


3.		Phase III Management and Prophylaxis of Fever and Infection with Antimicrobial Treatment in Cancer Patients (Study III)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				no age specified								NCI-81-C-189 NCI-POB-8103

Last Modified: 11/22/2006


4.		Phase III Comparison of ARA-C/DNM/TG vs ARA-C/VCR/DM for Remission Induction plus Intensive Multi-Drug Maintenance for Previously Untreated Pediatric ANLL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				21 and under				NCI				POG-8101 POG-ANLL-2, POG-8101

Last Modified: 6/14/2007


5.		NCI HIGH PRIORITY CLINICAL TRIAL --- Phase III Randomized Comparison of CHOP (CTX/ADR/VCR/PRED) vs m-BACOD (CTX/ADR/VCR/BLEO/DM/MTX/CF) vs ProMACE-CytaBOM (CTX/ADR/VP-16/PRED/ARA-C/BLEO/VCR/MTX/CF) vs MACOP-B (MTX/CF/ADR/VCR/BLEO/PRED) in Patients with Intermediate- or High-Grade non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				SWOG-8516 EST-3487, INT-0067


6.		Phase III Randomized Study of Initial Empiric Antimicrobial Therapy with TMP-SMX/Erythromycin and Other Antibiotics as Indicated vs Pretreatment Bronchoalveolar Lavage and Pathogen-Specific Therapy in Immunocompromised Patients with Diffuse Interstitial Pneumonitis (Summary last modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				no age specified				NCI				NCI-86-C-26 NCI-T86-0081N, T86-0081

Last Modified: 4/1/1997


7.		Phase III Pilot Chemotherapy with Short-Course ProMACE-CytaBOM (CTX/ADR/VP-16/ARA-C/BLEO/VCR/MTX/PRED) for the Treatment of Patients with Stages II-IV Diffuse Aggressive Lymphomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				over 18				NCI				CRB-8807E NCI-87-C-180C, NCI-T87-0307N, T87-0307

Last Modified: 4/23/2007


8.		Phase III Randomized Study of Continuous-Infusion vs Bolus High-Dose ARA-C During Induction and of Intensification with VP-16/IFF vs No Intensification in Children and Adolescents with Stage III/IV Diffuse Undifferentiated non-Hodgkin's Lymphoma or B-Cell ALL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				21 and under				NCI				POG-9317 POG-9317

Last Modified: 2/1/2001 First Published: 7/1/1994


9.		Phase II Study of ProMACE-CytaBOM with Co-Trimoxazole, Filgrastim (G-CSF) and Antiretroviral Therapy in Patients with AIDS-Related Lymphoma (Summary Last Modified 02/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 18				NCI				SWOG-9320 NCT00002571, SWOG-9320

Last Modified: 5/9/2006


10.		Phase II Pilot Study of Weekly Escalating Rotational Chemotherapy (VP-16/VCR, DOX/ARA-C, PEG-ASP/TIT, CTX/PRED, and MTX/MP) as Continuation Therapy in Children with Non-T, Non-B-Cell ALL in First Marrow Relapse, with Weekly vs Biweekly PEG-ASP During Induction: SIMAL #7

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				under 22 at initial diagnosis				NCI				POG-9310 POG-9310

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute